PHAXIAM Therapeutics (PHAXIAM Therapeutics) Long-Term Capital Lease Obligation : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PHAXIAM Therapeutics Long-Term Capital Lease Obligation?

PHAXIAM Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.

PHAXIAM Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 ($2.84 Mil) to Jun. 2023 ($2.77 Mil) and declined from Jun. 2023 ($2.77 Mil) to Sep. 2023 ($0.00 Mil).

PHAXIAM Therapeutics's annual Long-Term Capital Lease Obligation declined from Dec. 2020 ($11.19 Mil) to Dec. 2021 ($9.22 Mil) and declined from Dec. 2021 ($9.22 Mil) to Dec. 2022 ($2.84 Mil).

PHAXIAM Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for PHAXIAM Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics Long-Term Capital Lease Obligation Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

12.53

11.19

9.22

2.84

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															3.15	-	2.84	2.77	-

PHAXIAM Therapeutics (NAS:PHXM) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

PHAXIAM Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (PHAXIAM Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (NAS:PHXM) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PHXM:France 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.